U.S. Markets close in 2 hrs 41 mins
  • S&P 500

    4,243.74
    -11.41 (-0.27%)
     
  • Dow 30

    34,258.34
    -135.41 (-0.39%)
     
  • Nasdaq

    14,074.92
    -99.23 (-0.70%)
     
  • Russell 2000

    2,313.47
    -12.68 (-0.55%)
     
  • Crude Oil

    72.09
    +1.21 (+1.71%)
     
  • Gold

    1,854.80
    -11.10 (-0.59%)
     
  • Silver

    27.64
    -0.40 (-1.44%)
     
  • EUR/USD

    1.2130
    +0.0007 (+0.0606%)
     
  • 10-Yr Bond

    1.4970
    -0.0040 (-0.27%)
     
  • Vix

    17.14
    +0.75 (+4.58%)
     
  • GBP/USD

    1.4073
    -0.0035 (-0.2463%)
     
  • USD/JPY

    110.1060
    +0.0450 (+0.0409%)
     
  • BTC-USD

    40,317.88
    +333.13 (+0.83%)
     
  • CMC Crypto 200

    1,003.98
    -6.63 (-0.66%)
     
  • FTSE 100

    7,172.48
    +25.80 (+0.36%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Edwards Lifesciences's Earnings Outlook

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

On Wednesday, October 21, Edwards Lifesciences (NYSE: EW) will release its latest earnings report. Here is Benzinga's outlook for the company.

The Definitions Of Net Income, Earnings, And Earnings Per Share (EPS)

Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS.

Earnings And Revenue

Edwards Lifesciences earnings will be near $0.44 per share on sales of $1.08 billion, according to analysts. Edwards Lifesciences EPS in the same period a year ago totaled $1.41. Revenue was $1.09 billion.

What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a given company yields the "consensus estimates." If the company posts earnings or revenue above or below the consensus estimate, the stock may move by a considerable margin.

View more earnings on EW

The Wall Street estimate would represent a 68.79% decline in the company's earnings. Revenue would be down 1.28% from the year-ago period. The company's reported EPS has stacked up against analyst estimates in the past like this:

EPS Estimate

0.17

1.33

1.48

1.22

EPS Actual

0.34

1.51

1.46

1.41

Revenue Estimate

789.42 M

1.08 B

1.14 B

1.04 B

Revenue Actual

925.00 M

1.13 B

1.17 B

1.09 B

Stock Performance

Shares of Edwards Lifesciences were trading at $84.03 as of October 19. Over the last 52-week period, shares are up 12.68%. Given that these returns are generally positive, long-term shareholders are probably happy going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Edwards Lifesciences is scheduled to hold the call at 17:00:00 ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/edwds/mediaframe/40733/indexl.html

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.